• Anna Smith
• 17 Jul, 2019

PureTech Health has announced that it has acquired and plans to develop a clinical-stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema. The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies and was observed to be well tolerated with a favourable pharmacokinetic profile to support twice daily oral dosing.
Read more...